Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cerus Corporation(CERS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CERS
11/10/2026: CERS (1-star) is currently NOT-A-BUY. Pass it for now.
Cerus Corporation is a specialized medical technology company focused on enhancing blood transfusion safety through its proprietary INTERCEPT Blood System. The company's core strength lies in its pathogen reduction technology, which provides a unique and clinically validated solution that is gaining adoption in global markets. Its primary investment story centers on the scaling of this technology as an industry standard. However, investors must consider risks such as intense competition, slow adoption cycles, and the company's historical path to profitability. The stock may best suit growth investors comfortable with the risks of the medical device sector, with key developments to monitor including label expansions and international market penetration.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through the adoption of its proprietary blood safety technology but faces execution and market penetration risks. |
| Momentum investor | Weak fit | Momentum fit is conditional on a sustained positive upturn signal, which is not currently present. |
| Value investor | Weak fit | The company is not currently focused on value metrics like dividends or consistent GAAP profitability. |
| Dividend investor | Weak fit | Cerus does not pay a dividend, making it unsuitable for income-focused investors. |
| Low-risk investor | Weak fit | High volatility and the nature of the biotechnology sector pose significant risks to capital preservation. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences significant price swings common in development-stage or growth-oriented medical device companies. |
| Valuation risk | Medium / high | Future growth expectations are baked into the share price, leaving little room for execution errors. |
| Competition risk (Blood technology competition) | Medium | Larger, well-capitalized competitors can introduce alternative testing or safety technologies that could disrupt market share. |
| Business quality | Medium | The company operates in a niche, critical healthcare segment with defensible technology but remains early in its path to profitability. |
| Dividend income | Low / none | No dividends are paid, so income-seeking investors will not find this stock suitable. |
| Execution risk | Medium / high | Success depends on the continued adoption and integration of INTERCEPT by global blood centers, which can be a slow process. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -45.97% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 418.05M USD | Price to earnings Ratio - | 1Y Target Price 5.12 |
Price to earnings Ratio - | 1Y Target Price 5.12 | ||
Volume (30-day avg) 2.2M shares | Beta 1.85 | 52 Weeks Range 1.47 - 3.47 | Updated Date 11/10/2026 |
52 Weeks Range 1.47 - 3.47 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Sale of INTERCEPT Blood System disposable kits and illumination equipment. | Revenue is primarily generated from the recurring sale of consumable kits used in blood pathogen reduction processes. |
| Geography | Sales across North America, Europe, and other international regions. | International market expansion is a key driver for revenue diversification beyond the US. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 434.89M | Price to Sales(TTM) 1.85 |
Enterprise Value 434.89M | Price to Sales(TTM) 1.85 | ||
Enterprise Value to Revenue 1.87 | Enterprise Value to EBITDA 285.86 | Shares Outstanding 201.95M | Shares Floating 195.78M |
Shares Outstanding 201.95M | Shares Floating 195.78M | ||
Percent Insiders 3.61 | Percent Institutions 74.74 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.